Trump's psychedelics executive order

The order focuses on accelerating clinical trials for substances such as psilocybin, MDMA, and ibogaine as potential treatments for depression and PTSD. FDA Commissioner Marty Makary described the signing as an 'historic moment' that could transform mental health care in America.

Supporters believe the order will unlock stalled reforms and provide new options for veterans and patients who have not responded to traditional therapies.

Critics, however, have raised concerns about safety guardrails and the rapid commercialization of powerful hallucinogens.